Project Summary
Project P12 aims to uncover the mechanisms by which the BRAF-V600E mutation in malignant melanoma promotes immunosuppression within the tumour microenvironment, focusing specifically on the roles of Oncostatin M and prostaglandin E2 in modulating myeloid cells. To dissect this regulatory axis, we will employ in vitro co-culture systems as well as orthotopic and metastatic melanoma mouse models. As a translational approach, we will investigate the therapeutic potential of combining anti-OSMR antibodies with BRAF/MEK inhibitors and anti-PD-1 immunotherapy and validate our findings in human melanoma tissue samples.
